Ramipril in the treatment of vascular diseases.

Abstract:

:Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardiovascular death, myocardial infarction, stroke, congestive heart failure, progressive renal impairment and onset of diabetes. Ramipril is usually dosed at 2.5-10 mg/day. Beneficial effects of ramipril are observed in the treatment of hypertension and congestive heart failure, prevention of cardiovascular events in high-risk patients, prevention of congestive heart failure, diabetes and other vascular events.

authors

Rokoss MJ,Teo KK

doi

10.1517/14656566.6.11.1911

keywords:

subject

Has Abstract

pub_date

2005-09-01 00:00:00

pages

1911-9

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

6

pub_type

杂志文章,评审
  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.1.75

    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • The use of retinoids in the prevention and treatment of skin cancer.

    abstract::There has been a significant increase in the number of cases of skin cancer diagnosed in the US in the past few years. Thus, it seems appropriate to review the available compounds that might be used in the chemoprevention of these lesions. This review focuses on the retinoids and details their results in clinical tria...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.3.299

    authors: Niles RM

    更新日期:2002-03-01 00:00:00

  • Treatment options for chronic myeloid leukemia.

    abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.671296

    authors: Tanaka MF,Kantarjian H,Cortes J,Ohanian M,Jabbour E

    更新日期:2012-04-01 00:00:00

  • Is vaccine therapy the future in cancer prevention?

    abstract::One vaccine designed to prevent cancer by preventing a precursor infection is already in common use, and at least one more is in the latter stages of clinical development. These vaccines are part of a new era of cancer immunoprophylaxis. Several further vaccines are in preclinical and clinical development, targeted at...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.5.12.2427

    authors: Frazer I

    更新日期:2004-12-01 00:00:00

  • Pharmacotherapy of post-transplant viral infections.

    abstract:BACKGROUND:Management of a number of significant viral pathogens in transplant recipients remains challenging. OBJECTIVES:To define an optimal antiviral approach to the management of cytomegalovirus (CMV), human herpes virus-6 (HHV-6), Epstein-Barr (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.14.2409

    authors: Sun HY,Singh N

    更新日期:2008-10-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • Current and future therapies for gout.

    abstract:INTRODUCTION:Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia. The management of gout implies both the treatment of flares and the treatment of hyperuricaemia itself. Recent improvement in the understanding of the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1351945

    authors: Pascart T,Richette P

    更新日期:2017-08-01 00:00:00

  • Novelties in the multifaceted miconazole effects on skin disorders.

    abstract:BACKGROUND:Miconazole nitrate is a time-honored antifungal of the imidazole class. OBJECTIVE:To revisit the various aspects of action of the drug in a dermatologic setting. METHOD:Review of the current peer-reviewed publications. RESULTS/CONCLUSION:Miconazole essentially inhibits 14alpha-demethylase, an enzyme requi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.11.1927

    authors: Quatresooz P,Vroome V,Borgers M,Cauwenbergh G,Piérard GE

    更新日期:2008-08-01 00:00:00

  • Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

    abstract:INTRODUCTION:PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-medi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1737010

    authors: Kienle DL,Stilgenbauer S

    更新日期:2020-06-01 00:00:00

  • Review of vorapaxar for the prevention of atherothrombotic events.

    abstract:INTRODUCTION:Atherosclerosis is frequently caused by clot blockage of the coronary or peripheral arteries, and may lead to myocardial infarction (MI) or peripheral arterial disease (PAD). Despite advancements in management of atherosclerosis, mortality and ischemic rates remain high. Vorapaxar is a protease activated r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1099629

    authors: Wang A

    更新日期:2015-01-01 00:00:00

  • Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

    abstract:INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1811850

    authors: Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

    更新日期:2021-01-01 00:00:00

  • Assessment and management of acute pain in high-risk neonates.

    abstract::Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.475

    authors: Gibbins S,Stevens B,Asztalos E

    更新日期:2003-04-01 00:00:00

  • MP29-02: a breakthrough for the treatment of allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.828693

    authors: Bernstein JA

    更新日期:2013-10-01 00:00:00

  • Evaluating triptorelin as a treatment option for breast cancer.

    abstract::Introduction: Triptorelin is a luteinizing hormone-releasing hormone analog (LH-RHa) inducing ovarian function suppression (OFS). It is approved by FDA and EMA in association with tamoxifen or aromatase inhibitor (AI) and with fulvestrant and palbociclib in premenopausal women with hormone receptor (HR)-positive breas...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2019.1650020

    authors: Ferraro E,Trapani D,Marrucci E,Curigliano G

    更新日期:2019-10-01 00:00:00

  • Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

    abstract:INTRODUCTION:Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The eff...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.714368

    authors: Osman NI,Chapple CR,Cruz F,Desgrandchamps F,Llorente C,Montorsi F

    更新日期:2012-10-01 00:00:00

  • Current chemotherapy options for thymic epithelial neoplasms.

    abstract::Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for loca...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.7.1169

    authors: Papadopoulos KP,Thomas CR Jr

    更新日期:2005-06-01 00:00:00

  • Treating diabetic ulcers.

    abstract:INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.530658

    authors: Tecilazich F,Dinh T,Veves A

    更新日期:2011-03-01 00:00:00

  • Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.

    abstract:INTRODUCTION:Postprandial hyperglycemia (PPHG) contributes to micro- and macro-vascular complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, particularly Indians and Chinese need agents to control the higher risk of uncontrolled ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070827

    authors: Joshi SR,Standl E,Tong N,Shah P,Kalra S,Rathod R

    更新日期:2015-01-01 00:00:00

  • Pharmacological treatment for insomnia in patients with major depressive disorder.

    abstract:INTRODUCTION:Insomnia in Major Depressive Disorder (MDD) is highly prevalent and associated with increased suffering and functional impairment. Effective, evidence-based treatments for insomnia in MDD are an unmet need in clinical practice. AREAS COVERED:Herein, the authors provide a review of the clinical correlates,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1614562

    authors: Brietzke E,Vazquez GH,Kang MJY,Soares CN

    更新日期:2019-08-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Pharmacological treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618496

    authors: Reinhold JA,Mandos LA,Rickels K,Lohoff FW

    更新日期:2011-11-01 00:00:00

  • Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.

    abstract::The introduction of anti-TNFalpha therapy into the field of rheumatology has led to dramatic improvements in patient care, perhaps the most remarkable being in the management of ankylosing spondylitis. As experience with these compounds grows, their place in therapeutic strategy is becoming clearer, and it has been po...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.7.869

    authors: Zochling J,Braun J

    更新日期:2006-05-01 00:00:00

  • Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.

    abstract:INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1828350

    authors: Panza F,Lozupone M,Watling M,Imbimbo BP

    更新日期:2020-10-06 00:00:00

  • Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.

    abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.9.1235

    authors: Antoniu SA

    更新日期:2006-06-01 00:00:00

  • Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

    abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.9.9.1619

    authors: Doggrell SA

    更新日期:2008-06-01 00:00:00

  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

    abstract:INTRODUCTION:The epidermal growth factor receptor (EGFR) is mutated in 15% of adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered in 8% of adenocarcinomas of the lung. Treatment of EGFR mutant and ALK translocation-positive tumors in NSCLC with tyrosine kinase inhibitors (TKI) resu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.971013

    authors: Somasundaram A,Socinski MA,Burns TF

    更新日期:2014-12-01 00:00:00

  • Autism unravelled conference--'the biology of autism--unravelled'.

    abstract::Autism is a heterogeneous condition, currently with no single explanation for all of these findings presented at this conference. What conferences like this offer us, however, are possible courses of new research and the subsequent development of intervention strategies, both orthodox (pharmacological) and perhaps sli...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:

    authors: Whiteley P

    更新日期:2001-07-01 00:00:00

  • Paroxetine mesylate: comparable to paroxetine hydrochloride?

    abstract:IMPORTANCE OF THE FIELD:Currently available small case reports clearly propose that existing regulatory procedures to approve generic versions only require essential bioequivalence, have limitations and fail to meet stricter scientific and clinical demands. AREAS COVERED IN THIS REVIEW:Data indicate that paroxetine me...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903451708

    authors: Pae CU,Misra A,Ham BJ,Han C,Patkar AA,Masand PS

    更新日期:2010-02-01 00:00:00

  • Current pharmacotherapy options for gastritis.

    abstract:INTRODUCTION:Gastritis is a broad term, which is used for different conditions by clinicians, endoscopists and pathologists. Classification strategies have led to more congruence between specialists. The histological evaluation of the gastric mucosa is mandatory for diagnosing and classifying gastritis. Main aetiologic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.747510

    authors: den Hollander WJ,Kuipers EJ

    更新日期:2012-12-01 00:00:00